Connect with BUHLMANN at UEGW2017

United European Gastroenterology Week (UEGW) 2017

BUHLMANN Laboratories AG

Booth: #64 Hall 8.1
Oct 28 – Nov 1, 2017

LOCATION
Fira de Barcelona Gran Via
Barcelona, Spain

Take the chance to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio:

Quantum Blue® platform offering rapid and quantitative results for fecal calprotectin, serum calprotectin, CRP and serum infliximab trough levels. Additional trough level assays coming soon!

IBDoc® calprotectin home test for remote monitoring of IBD patients in remission

BÜHLMANN fCAL® ELISA, the gold standard assay for fecal Calprotectin

BÜHLMANN fCAL® turbo, the new high troughput, random access fecal Calprotectin assay. Available for virtually all Clinical Chemistry Analyzers allowing time to result of 10 minutes.

CALEX® Cap, the new standard in stool extraction

Schuster T. et al.: P1014 – Performance of the BÜHLMANN Quantum Blue® Adalimumab rapid test dedicated for therapeutic drug monitoring of serum adalimumab trough levels

Conclusions:The BÜHLMANN Quantum Blue® Adalimumab lateral flow test enables the quantitative determination of adalimumab trough level in serum with time to result of only 15 minutes. The developed test allows to measure adalimumab over a wide range, well beyond the therapeutic window. Hence, it represents a valuable tool for the clinician to assess the adalimumab trough level.

 

Magro F. et al.: P1022 Clinical perspective on drug monitoring with an infliximab rapid quantification assay

Conclusion:Our results show that the rapid IFX assessment system is a reliable alternative to the time-consuming ELISAs in patients in the maintenance phase of IFX operating a threshold of 3 ug/ml.

El-Safi G. et al. P1675:  Cost effectiveness of IBDoc faecal calprotectin as a surrogate marker of mucosal healing post induction of biological agents in inflammatory bowel disease.

Conclusion:This study demonstrates a significant cost-effectiveness of using IBDoc faecal calprotectin post induction of anti-TNF therapy, as well as reducing the waiting time for both clinic visits and colonoscopy.

Walsh A. et al, P1641: TrueColours ulcerative colitis (TCUC): Will patients with UC complete digital questionnaires in Real-Time?

Conclusion:  “Patients with UC will collect digital data in real-time, with good adherence to symptom, QoL, outcome questionnaires and FCal home testing. Usability was classified as ‘superior’ but further improvements are possible. Larger studies are required to determine cost-effectiveness.

Puolanne M. et al: P0371 – Self-monitoring of the colonic inflammatory bowel disease by a rapid home based feacal calprotectin test and a symptom questionnaire.

Conclusion:The self-monitoring of IBD activity with a rapid FC home test provides an option for individualized treatment for increasing amount of IBD patients…

Impressions from BÜHLMANN at UEGW 2016 and two TDM live poster presentations